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osting by EAbstract Leprosy reactions are rare expression of immunological perturbations that interrupt the
usual chronic course and the clinical stability of patients with leprosy. Erythema nodosum leprosum
(ENL) is an immune complex-mediated reaction that may complicate the course of multibacillary
leprosy. It generally occurs during antimycobacterial treatment and characterized by the appear-
ance of crops of brightly erythematous tender nodules or plaques. Severe ENL can become vesicular
or bollous and break-down and is termed erythema necroticans [Jobling, W.H., Mc Dougall, A.C.,
1996. Leprosy reactions. In: Handbook of leprosy, 5th ed. CBS Publishers, New Delhi, pp. 82–91].
We present here a case of erythema necroticans, misdiagnosed as sweet’s syndrome, because he had
never been presented with pre-existing evidence of leprosy nor had any antimycobacterial treat-
ment. The clinical diagnosis is conﬁrmed by microscopic pathology. The lesions resolved completely
following multibacillary MDT, corticosteroids and Azathioprine.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Leprosy is a disease of slow development that presents a wide
spectrumof clinical, histopathological and immunological char-
acterization. Leprosy reactions are rare and not well-known
states that interrupt the usual chronic course and the clinical sta-
bility of patients with leprosy. They are expression of immuno-393331; fax: +974 4393058.
(N. Al Hayki).
y. Production and hosting by
Saud University.
lsevierlogical perturbations (Sehgal et al., 1988). Erythema nodosum
leprosum (ENL) is an immune complex-mediated reaction that
may complicate the course ofmultibacillary leprosy. It generally
occurs during antimycobacterial treatment and characterized by
the appearance of crops of brightly erythematous tender nod-
ules or plaques. Severe ENL can become vesicular or bollous
and break-down and is termed erythema necroticans (Jobling
and Mc Dougall, 1996). The extra Cutaneous manifestation
include neuritis, iridocyclitis, orchitis and lymphadenopathy.
Fever and other constitutional symptoms are usually associated
with it (JesU´s et al., 2007).We present here a case of necrotic ery-
thema nodosum leprosum, misdiagnosed as sweet’s syndrome,
because he had never been presented with pre-existing evidence
of leprosy nor had any antimycobacterial treatment.
2. Case report
A 44 years old diabetic male from Indonesia, was referred
from a private clinic for management of recurrent attacks of
64 N. Al Hayki, B. Al-Mahmoudsevere and extensive painful skin lesions associated with fever
and deteriorating general condition. He has been diagnosed
clinically as Sweet’s syndrome and received monthly injections
of steroids during the past one year to control the attacks. On
examination, the patient had fair general condition, cushingoid
features. There are multiple geographic brownish macules all
over his trunk and extremities. The condition was diagnosed
as postinﬂammatory hyperpigmentation and treated as such.
The patient has been advised to return to the clinic with any
new lesion. Within one month, the patient came to the clinic
by wheel chair. He presented with high grade, intermittent fe-
ver, with other systemic symptoms such as, bone tenderness,
myalgia, ankle and knee arthralgia, neuritis, edema and mal-
aise. He developed crops of painful skin lesions all over the
body including the face over a few days. He had similar recur-
rent episodes during the last 12 months. The patient had never
presented with chronic skin lesions or neurologic deﬁcit sug-
gestive of leprosy. On admission, he was found having
cushingoid features. There were multiple painful erythematous
tender nodules, erythema multiform-like lesions and skin
necrosis of various sizes present over the trunk and extremities,
several of them with ﬂaccid blister, sometime hemorrhagic or
seropurulent (Fig. 1A–E). The joints were mildly swollen andFigure 1 (A–E) Multiple painful erythematous tender nodules. Eryt
present over the trunk and extremities, several of them with ﬂaccid bl
Figure 2 (A–C) Histopathologic analysis showed poorly deﬁnes epi
cells including neutrophils, lymphocytes and rare eosinophils centered
superﬁcial, mid and deep dermis.tender. The ulner, lateral popliteal and great auricular nerves
were thickened. Histopathologic analysis showed poorly de-
ﬁned epithelioid granulomas with lepra cells and numerous
inﬂammatory cells including neutrophils, lymphocytes and
rare eosinophils centered around blood vessels, nerves and ad-
nexal structure occupying the superﬁcial, mid and deep dermis
(Fig. 2A–C). Fite stain shows numerous acid fast organisms
(Fig. 3). Slit skin smear from the lesion showed BI of 3+,
while IgM antiphenolic glycolipid I (anti-PGL-I) ﬁndings were
negative. All routine investigations were within normal limits
except for raised ESR, C-reactive protein (CRP) and leukocy-
tosis. Examination of other systems reveal high liver enzymes,
otherwise it was unremarkable. Ocular examination and chest
X-ray did not reveal any abnormality.
The diagnosis of borderline lepromatous leprosy presenta-
tion with necrotic and bollous type eryhema nodosum lepro-
sum was made. He started on (WHO) MB-MDT therapy
along with 40 mg daily prednisolone. After improvement of
general condition, the ENL reaction was controlled and the
patient became asymptomatic. He was discharged after two
weeks on (WHO) MB-MDT therapy and with gradual taper-
ing of the prednisolone over one month and stopped. One
month after stopping prednisolone, the patient developed ahema multiform like lesions and skin necrosis of varied sizes were
ister, sometime hemorrhagic or seropurulent.
thelioid granulomas with lepra cells and numerous inﬂammatory
around blood vessels, nerves and adnexal structure occupying the
Figure 3 Fite stain shows numerous acid fast organisms.
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associated with fever and joint pain. The dose of prednisolone
increased to 80 mg daily orally for 2 weeks. But, there was no
adequate control of ENL with this treatment, moreover, he
continued to develop new lesions with persistence of the fever
and joint pain. Second-line drug such as Thalidomide has been
suggested. Thalidomide was not available in our center. The
patient was treated with (WHO) MB-MDT, prednisolone re-
duced to 40 mg daily. Azathioprine was added at a dose of
100 mg daily (2 mg/kg /day). ENL lesions started healing with
complete relief within 4 weeks. Prednisolone was reduced by
10 mg every week and then stopped after 4 weeks, while Aza-
thioprine 50 mg daily was continued for 6 months then
stopped. Complete blood count, liver and renal function tests
were repeated every month during the azathioprine treatment
which remained unremarkable. The ENL never recurred.
3. Discussion
Erythema nodosum leprosum (ENL) is an immune complex-
mediated reaction that may complicate the course of multibac-
illary leprosy and characterized by the appearance of crops of
brightly erythematous tender nodules or plaques. Severe ENL
can become vesicular or bollous and break-down and is termed
erythema necroticans (Jobling and Mc Dougall, 1996). The
small number of reported cases in the world literature suggests
that it is fairly uncommon (Verma and Pandhi, 1993; Davis
et al., 2002; Pandhi et al., 2005; Athanasia et al., 2008;
Zannatun et al., 2009). Our patient shows polymorphic lesions
clinically, less nodular than classical ENL, which is mainly
seen in the trunk, but has more erythematous, or violaceous
macules and plaques distributed on the extremities. The
plaques have vesicles, bullae and necrotic skin.
Although erythema nodosum leprosum occurs usually dur-
ing the treatment of lepromatous leprosy, there have been a
fair number of reports of untreated lepromatous leprosy with
subtle initial changes, presenting de novo as ENL, or may
present with extraordinary manifestations, often with long de-
lay before the diagnosis of leprosy is considered (Zannatun
et al., 2009; Mc Dogall and Archibald, 1977). Here, we de-
scribe a case present with necrotic ENL as presenting manifes-
tation of subtle borderline lepromatous leprosy; he had no
previous evidence of neurologic deﬁcit or chronic skin lesions
suggestive of this chronic infection. The condition was difﬁcult
to diagnose clinically; numerous tender nodules and plaques
and necrotic lesions with seropurulent blisters led to the initial
misdiagnosis of Sweet’s Syndrome. But, what provokes the
subtle leprosy from its dormant to express ENL reaction?
The probable trigger factors associated with ENL reactioninclude surgical operations, pregnancy, parturition, lactation,
menstruation, trauma, intercurrent illness, vaccination, physi-
cal or mental stress and some time therapy (Verma and
Pandhi, 1993; Zannatun et al., 2009). Tumor necrosis factor-
a (TNF-a), a pro-inﬂammatory cytokine, plays an important
role in the pathogenesis of ENL. There is activation of T-cell
and macrophages, inducing production of large amounts of
TNF-a (Kaushal et al., 2006). Additional source of TNF-a is
the severe leukocytosis and the intense neutrophil inﬁlterate
in ENL lesions. Plasma levels of this cytokine have been found
to be high during the episode of ENL (Sehgal et al., 1988).
High CRP levels along with a positive correlation between ele-
vated TNF-a and CRP levels in the serum of ENL patients has
been reported (Foss et al., 1993). In the present case, the pa-
tient presented with high serum level of CRP that regressed
by the end of the attacks. Taken together, leukocytosis,
TNF-a and CRP could be considered as laboratory parame-
ters to be used to follow up the acute inﬂammatory response
in ENL (Foss et al., 1993). The management of ENL is a real
challenge for clinicians; ENL has usually a relapsing and
remitting course that may last for several years, ENL produce
greater disability than the underlying lepromatous leprosy and
was the commonest reason for admission to the hospital (Levy
et al., 1973). Three types of ENL were identiﬁed: single acute
ENL, multiple acute ENL (repeated discrete episodes) and
chronic ENL (continuous episodes). 92% of ENL reactions
are usually chronic and relapsing with unpredictable clinical
course (Eonor et al., 2006). Our patient has almost nine recur-
rent episodes of ENL during the last 12 months.
Multiple drug therapy (MB-MDT) for borderline leproma-
tous leprosy should preferably be taken as per the recommen-
dations of WHO (Eonor et al., 2006). In addition, treatment
with prednisolone should be instituted for 12 weeks course.
This overlooks the chronic, recurrent nature of ENL (WHO,
1998). Although prednisolone is used as the ﬁrst-line drug
for treating moderate and severe ENL, its effect in managing
patients with ENL is less than adequate (Eonor et al., 2006).
The WHO has recommended the antiinﬂammatory clofazi-
mine for chronic and severe ENL and as steroid-sparing agent
(Pannikar, 2003). However, it takes 4–6 weeks for the effect of
clofazimine to be clinically detectable. Thus, it is not useful for
the management of acute ENL (Eonor et al., 2006; WHO,
1998). Clofazimine 100 mg tablets are available only in MDT
blister packs for the patients in our center.
Thalidomide is now considered the drug of choice for ENL.
It was approved by the FDA in 1998 in the acute treatment of
moderate to severe ENL and preventing new episodes
(www.fda.gov). There are serious limitations to its use due to
its teratogenic effects and potential neurotoxicity, causing it
to be banned in many countries (Pannikar, 2003). Our patient
may have beneﬁted from this drug, but it is not available in our
center, and the cost is out of reach of the patient. The search
for an effective alternatives, led to experiencing second-line
drugs such as pentoxifyline (Sales et al., 2007), mycophenolate
mofetil (Kalian and Raghubir, 2008), Azathioprine (Kaushal
et al., 2006) and inﬂiximab (Williame et al., 2006) with incon-
sistent results. We have chosen Azathioprine for our patient
because it has strong antiinﬂammatory effect and has also been
shown to inhibit TNF-a. The drug has been effectively used on
long-term basis as a steroid-sparing agent. Its long-term safety,
adverse effects and monitoring have been well studied
(Kaushal et al., 2006).
66 N. Al Hayki, B. Al-Mahmoud4. Conclusion
We report this case because experience shows that in non-
endemic areas such as State of Qatar and with the growing
number of immigrants arriving for work, diagnostic dilemma
posed in correctly identifying patients with chronic infectious
diseases such as leprosy, lead to long delay before the correct
diagnosis was considered, and subsequently the use of inappro-
priate therapies such as corticosteroids, which can potentially
worsen the disease. Practicing physicians need to have a high
clinical index of suspicion and to be aware of the extraordinary
presentation of the different chronic infectious diseases that
make them hard to diagnose.
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